Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Sarclisa - opinion on variation to marketing authorisation

Sarclisa - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation.

isatuximab
Post-authorisationHuman

Page contents

  • Opinion
  • Key facts
  • News on Sarclisa
  • More information on Sarclisa

Opinion

On 14 November 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sarclisa. The marketing authorisation holder for this medicinal product is Sanofi Winthrop Industrie.

The CHMP adopted a new indication as follows:

Sarclisa is indicated:

  • in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

For information, the full indications for Sarclisa will be as follows1:

Sarclisa is indicated:

  • in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.
  • in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).
  • in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR) and made available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1 New text in bold

CHMP post-authorisation summary of positive opinion for Sarclisa (II-30)

AdoptedReference Number: EMA/CHMP/508897/2024

English (EN) (159.75 KB - PDF)

First published: 15/11/2024
View

Key facts

Name of medicine
Sarclisa
EMA product number
EMEA/H/C/004977
Active substance
Isatuximab
International non-proprietary name (INN) or common name
isatuximab
Therapeutic area (MeSH)
Multiple Myeloma
Anatomical therapeutical chemical (ATC) code
L01XC38
Marketing authorisation holder
Sanofi Winthrop Industrie
Date of opinion
14/11/2024
Status
Positive

News on Sarclisa

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024
15/11/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021
26/02/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated)
27/03/2020

More information on Sarclisa

  • Sarclisa
This page was last updated on 15/11/2024

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union